Holen Sie sich die Stockscreener-App
200.91
1.12%
-2.28
Handel nachbörslich:
200.77
-0.14
-0.07%
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera Expands Austin Operations With New Sequencing Facility - Yahoo Finance
Natera enhances prenatal test, cuts no-call rate to 0.5% - Investing.com
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology - Yahoo Finance
(NTRA) Risk Channels and Responsive Allocation - Stock Traders Daily
Natera's EXPAND trial enrollment crosses 2,000 patient milestone - MSN
Natera, Inc. (NTRA) Stock Analysis: Riding High On A 28.4% Potential Upside - DirectorsTalk Interviews
What's Driving Natera's Recent Stock Action - Kavout
How The Natera (NTRA) Investment Story Is Shifting With New Guidance And Analyst Revisions - Yahoo Finance
Is It Time To Reconsider Natera (NTRA) After Its Strong Five Year Share Price Gain - simplywall.st
NTRA Stock Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology - BioSpace
Natera to present 35 oncology abstracts at ASCO meeting By Investing.com - Investing.com South Africa
Natera to present 35 oncology abstracts at ASCO meeting - Investing.com UK
Mid-Cap Stocks Analysis: Natera to Buy, Graco and Jacobs Solutions to Sell | StockStoryNews and Statistics - IndexBox
35 Natera studies test ctDNA to flag cancer return at ASCO - Stock Titan
A Quick Look at Today's Ratings for Natera(NTRA.US), With a Forecast Between $220 to $285 - Moomoo
Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone - The Globe and Mail
Natera announces expansion into Austin, creating largest sequencing factory - TipRanks
Natera Expands Operations in Austin - Moomoo
Natera expands Austin facility, plans to add 400 jobs - Investing.com
Natera expands Austin facility, plans to add 400 jobs By Investing.com - Investing.com Canada
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World - Yahoo Finance
What's Driving Natera's Recent Stock Action, and Why Are Insiders Selling? - Kavout
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera (NTRA) Expands Clinical Trial Enrollment to Over 2,000 Pa - GuruFocus
Natera Expands Enrollment in Fetal Genetic Testing Study - Moomoo
Quinn Emanuel Gets $3 Million Sanction in Drug Advertising Case - Bloomberg Law News
Natera’s EXPAND trial enrolls over 2,000 patients - Investing.com UK
Natera’s EXPAND trial enrolls over 2,000 patients By Investing.com - Investing.com Australia
Study of prenatal gene risk test now passes 2,000 patients - Stock Titan
Quinn Emanuel Owes More Sanctions In Guardant Fight - Law360
FDA Nod For Signatera MRD Blood Test Might Change The Case For Investing In Natera (NTRA) - simplywall.st
Is It Time To Reassess Natera (NTRA) After The Recent Share Price Pullback - Yahoo Finance
Natera jumps after Signatera CDx wins FDA companion diagnostic approval in bladder cancer - Quiver Quantitative
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer - The Globe and Mail
Natera wins FDA approval for companion diagnostic - MedTech Dive
What's Behind Natera CEO Steven Chapman's Recent Stock Sales - Kavout
5 Must-Read Analyst Questions From Natera’s Q1 Earnings Call - Yahoo Finance
A Look At Natera (NTRA) Valuation After Recent Share Price Weakness - simplywall.st
Natera, Inc. (NTRA) Investor Outlook: Exploring A 39.99% Upside With Strong Buy Ratings - DirectorsTalk Interviews
Natera, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman - GuruFocus
Natera Inc stock (US6323071042): insider selling and a sharp pullback unsettle investors - AD HOC NEWS
Natera Scores Rare FDA Approval but Shares Drop - TechStock²
Natera co-founder Sheena Jonathan sells $959,450 in company stock - Investing.com India
Natera co-founder Sheena Jonathan sells $959,450 in company stock By Investing.com - Investing.com UK
Natera (NTRA) co-founder Jonathan Sheena sells 4,650 shares under 10b5-1 plans - Stock Titan
New blood test helps tailor bladder cancer treatment, wins FDA backing - Stock Titan
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod - Fierce Pharma
Natera's Signatera CDx Approved by FDA as Companion Diagnostic in Muscle-Invasive Bladder Cancer - Moomoo
Natera Gets FDA Approval for Bladder-Cancer Test - marketscreener.com
Natera’s Stronghold in Cancer Recurrence Tests Prompts Wood’s Ark to Expand Stake - The Daily Upside
(NTRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
3.51%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):